ENOUGH

ENOUGH (formerly 3F Bio) is a spinout of the University of Strathclyde that produces an alternative protein called “Abunda” mycoprotein by feeding fungi with renewable sugar feedstocks, such as wheat and corn, in a continuous fermentation process. Abunda claims to be taste-neutral and highly nutritious, rich in protein and fiber, and naturally fortified in B12, zinc, and iron. The company markets it as a base ingredient for the production of alternative meats and dairy products.

In September 2022 , ENOUGH inaugurated its flagship mycoprotein facility in the Netherlands supported by Circular Bio-based Europe Joint Undertaking (CBE JU), with EUR 16.9 million (~USD 16.9 million) from European funds aimed at bio-based industries as a part of the Plenitude project. The plant will have a capacity of 10,000 tons of protein initially, which is slated to increase to 50,000 tons by 2027. The company aims to produce more than a million tons of protein by 2032 in the new factory, equivalent to replacing 5 million cows, 1 billion chickens, and 30 million trees. 

Key customers and partnerships

In November 2020, Marks & Spencer‘s food division M&S Food partnered with ENOUGH to incorporate Abunda into its vegan Plant Kitchen range. Later, in May 2021, the company partnered with Unilever, to use Abunda in its alternative meat brand The Vegetarian Butcher.

In February 2024 , the company expanded its partnership with global food corporation Cargill. As a part of the expansion, Cargill was to participate in ENOUGH’s Series C funding round, co-create alternative proteins using Abunda, and help marketing efforts.

Funding and financials

ENOUGH’s latest funding round was in August 2023 , when it raised EUR 40 million (~USD 43.5 million) in funding co-led by World Fund and CPT Capital with participation from existing investors such as AXA IM Alts, HAL Investments, Onassis Group, and others. The funding was intended for doubling the output capacity of the Netherlands production site and increasing its teams across its Glasgow, London, and Sas van Gent offices.